Physician profile
Robert L Rice
NPI 1194722579
$1,980.92
in general payments reported to CMS, 2019-2025
21 companies · $20.48 in 2025
The $20.48 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $421 · 2021: $555 · 2022: $390 · 2023: $153 · 2024: $289 · 2025: $20.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $272.67 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $232.60 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $194.31 | 2019-2023 | Austedo |
| Supernus Pharmaceuticals, INC. | $191.01 | 2021-2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $115.47 | 2020-2022 | |
| Allergan, INC. | $114.72 | 2020 | |
| Alkermes, INC. | $111.17 | 2020-2022 | |
| Axsome Therapeutics, INC. | $100.37 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $96.62 | 2021-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Bausch Health US, LLC | $91.36 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.77 | 2020-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $70.12 | 2020-2021 | |
| Lundbeck LLC | $67.72 | 2019-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $54.40 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $40.01 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $37.86 | 2022-2024 | Azstarys |
| Tris Pharma INC | $30.55 | 2023-2024 | Dyanavel Xr |
| Eisai INC. | $27.18 | 2020 | |
| Jazz Pharmaceuticals INC. | $20.76 | 2021 | |
| Sun Pharmaceutical Industries INC. | $20.20 | 2020 | |
| Noven Therapeutics, LLC | $15.05 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.